Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
The pro-apoptotic lipid sphingosine is phosphorylated by sphingosine kinases 1 and 2 (SK1 and SK2) to generate the mitogenic lipid sphingosine-1-phosphate (S1P). We previously reported that inhibition of SK activity delays tumor growth in a mouse mammary adenocarcinoma model. Because SK inhibitors and the multikinase inhibitor sorafenib both suppress the MAP kinase pathway, we hypothesized that their combination may provide enhanced inhibition of tumor growth. Therefore, we evaluated the effects of two SK inhibitors, ABC294640 (a SK2-specific inhibitor) and ABC294735 (a dual SK1/SK2 inhibitor), alone and in combination with sorafenib on human pancreatic adenocarcinoma (Bxpc-3) and kidney carcinoma (A-498) cells in vitro and in vivo. Exposure of either Bxpc-3 or A-498 cells to combinations of ABC294640 and sorafenib or ABC294735 and sorafenib resulted in synergistic cytotoxicity, associated with activation of caspases 3/7 and DNA fragmentation. Additionally, strong decreases in ERK phosphorylation were observed in Bxpc-3 and A-498 cells exposed to either the sorafenib/ABC294640 or the sorafenib/ABC294735 combination. Oral administration of either ABC294640 or ABC294735 to mice led to a delay in tumor growth in both xenograft models without overt toxicity to the animals. Tumor growth delay was potentiated by co-administration of sorafenib. These studies show that combination of an SK inhibitor with sorafenib causes synergistic inhibition of cell growth in vitro, and potentiates antitumor activity in vivo. Thus, a foundation is established for clinical trials evaluating the efficacy of combining these signaling inhibitors.
Beljanski
Vladimir
V
Drug Discovery Core, Hollings Cancer Center and Department of Pharmaceutical and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA.
Knaak
Christian
C
Zhuang
Yan
Y
Smith
Charles D
CD
D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000633:toxicity; D001557:Benzenesulfonates / Q000008:administration & dosage; D053148:Caspase 3 / Q000378:metabolism; D053179:Caspase 7 / Q000378:metabolism; D002396:Catechols / Q000008:administration & dosage; D045744:Cell Line, Tumor; D053938:DNA Fragmentation / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D009536:Niacinamide / Q000031:analogs & derivatives; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010671:Phenylurea Compounds; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D023041:Xenograft Model Antitumor Assays; D000099157:Sphingosine Kinase
D000218:Adamantane; D001557:Benzenesulfonates; D053148:Caspase 3; D053179:Caspase 7; D002396:Catechols; D009536:Niacinamide; D010671:Phenylurea Compounds; D017853:Phosphotransferases (Alcohol Group Acceptor); D011725:Pyridines; D000077157:Sorafenib; D000099157:Sphingosine Kinase; C569360:3-(4-chlorophenyl)adamantane-1-carboxylic acid 3,4-dihydroxybenzylamide; C548780:3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
Cancer. 2005 Dec 1;104(11):2323-33
16240452
J BUON. 2009 Jul-Sep;14(3):399-404
19810129
Cell Signal. 2007 Feb;19(2):229-37
16963225
Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):413-28
17242884
N Engl J Med. 1996 Sep 19;335(12):865-75
8778606
Nat Rev Mol Cell Biol. 2008 Feb;9(2):162-76
18216772
Blood. 2005 Sep 1;106(5):1808-16
15890687
J Med Chem. 2007 Aug 23;50(17):4122-34
17658777
Subcell Biochem. 2008;49:413-40
18751921
Cancer Res. 2005 Mar 15;65(6):2412-21
15781657
J Pharmacol Exp Ther. 2010 May;333(2):454-64
20179157
Ann Surg Oncol. 2006 Jul;13(7):933-9
16788754
Mol Cancer Ther. 2005 Apr;4(4):677-85
15827342
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
17016424
Mol Cancer Ther. 2008 Oct;7(10):3129-40
18852116
Biochem J. 2005 Jun 15;388(Pt 3):827-34
15693752
J Biol Chem. 2007 Apr 13;282(15):10922-34
17303574
Cancer Res. 2003 Sep 15;63(18):5962-9
14522923
Leukemia. 2002 Sep;16(9):1596-602
12200669
J Pharmacol Exp Ther. 2010 Apr;333(1):129-39
20061445
Adv Cancer Res. 2009;102:1-17
19595305
Recent Results Cancer Res. 2010;180:137-63
20033382
Autophagy. 2008 Feb;4(2):151-75
18188003
J Pharmacol Exp Ther. 2006 Aug;318(2):596-603
16632640
Adv Enzyme Regul. 1984;22:27-55
6382953
Circulation. 2003 Jul 22;108(3):342-7
12847068
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):5022-31
17065523
Mol Cancer Ther. 2007 Jan;6(1):193-202
17237279
Anticancer Drugs. 2009 Nov;20(10):893-900
19752718
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
2359136
Mol Cell. 2006 Apr 21;22(2):217-30
16630891
Cell Signal. 2002 Dec;14(12):989-97
12359304
FEBS Lett. 2005 Oct 10;579(24):5313-7
16194537
Oncogene. 2003 Sep 1;22(37):5897-906
12947396